Related references
Note: Only part of the references are listed.Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Emerging Role of Interleukin-1β in Autoinflammatory Diseases
Helen J. Lachmann et al.
ARTHRITIS AND RHEUMATISM (2011)
Long-Term Efficacy of the Interleukin-1 Receptor Antagonist Anakinra in Ten Patients With Neonatal-Onset Multisystem Inflammatory Disease/Chronic Infantile Neurologic, Cutaneous, Articular Syndrome
Benedicte Neven et al.
ARTHRITIS AND RHEUMATISM (2010)
Mechanism-based concepts of size and maturity in pharmacokinetics
B. J. Anderson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models:: The npde add-on package for R
Emmanuelle Comets et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2008)
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease:: preliminary experience in France
T. Lequerre et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software
Marc Lavielle et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
V Pascual et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)